Ceribell, INC. (CBLL) — SEC Filings

Overview

Ceribell, INC. (CBLL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 9, 2025: Ceribell, Inc. filed an 8-K on December 9, 2025, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Sentiment Summary

Across 25 filings, the sentiment breakdown is: 23 neutral, 2 mixed. The dominant filing sentiment for Ceribell, INC. is neutral.

Filing Type Overview

Ceribell, INC. (CBLL) has filed 12 8-K, 4 10-Q, 1 DEFA14A, 1 DEF 14A, 1 10-K, 1 SC 13G, 1 SC 13D, 3 S-1/A, 1 S-1 with the SEC between Aug 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (25)

• 8-K Filing — 8-K · Dec 12, 2025
• Ceribell, Inc. Files 8-K — 8-K · Dec 9, 2025 Risk: low
  Ceribell, Inc. filed an 8-K on December 9, 2025, to report other events and financial statements. The filing does not contain specific details about the nature
• 8-K Filing — 8-K · Nov 24, 2025
• Ceribell's Revenue Jumps 37%, But Losses Widen Amid Soaring Costs — 10-Q · Nov 4, 2025 Risk: high
  Ceribell, Inc. (CBLL) reported a significant increase in total revenue for the nine months ended September 30, 2025, reaching $64.279 million, up from $46.910 m
• Ceribell, Inc. Files 8-K for Material Definitive Agreement — 8-K · Sep 24, 2025 Risk: medium
  On September 22, 2025, Ceribell, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this a
• Ceribell Appoints New CMO and Board Member — 8-K · Sep 22, 2025 Risk: medium
  Ceribell, Inc. announced on September 17, 2025, changes in its executive and director positions. Dr. Shayan Mostajabi has been appointed as Chief Medical Office
• Ceribell's Q2 Loss Widens to $15.3M Despite 22.5% Revenue Jump — 10-Q · Aug 5, 2025 Risk: high
  Ceribell, Inc. reported a net loss of $15.3 million for the three months ended June 30, 2025, compared to a net loss of $14.8 million for the same period in 202
• Ceribell, Inc. Files 8-K — 8-K · Jul 7, 2025 Risk: low
  Ceribell, Inc. filed an 8-K on July 7, 2025, to report other events and financial statements. The filing does not contain specific details about the nature of t
• Ceribell, Inc. Files 8-K for Material Definitive Agreement — 8-K · Jun 20, 2025 Risk: medium
  On June 12, 2025, Ceribell, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this agreem
• Ceribell, Inc. Reports on Security Holder Vote — 8-K · Jun 12, 2025 Risk: low
  Ceribell, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of its security holders on June 10, 2025. The filing does not detail the
• Ceribell, Inc. Files Proxy Statement Amendment — DEFA14A · Jun 9, 2025 Risk: low
  Ceribell, Inc. filed an amendment (Amendment No. 1) to its Schedule 14A on June 9, 2025. This filing is considered Definitive Additional Materials and does not
• Ceribell, Inc. Q1 2025 10-Q Filing — 10-Q · May 8, 2025 Risk: medium
  Ceribell, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including its venture loan and security agre
• Ceribell, Inc. Files 2025 Proxy Statement — DEF 14A · Apr 30, 2025 Risk: low
  Ceribell, Inc. filed its definitive proxy statement for the 2025 Annual Meeting of Stockholders, scheduled for April 30, 2025. The filing, designated as DEF 14A
• Ceribell, Inc. Files 8-K: Regulation FD & Financials — 8-K · Apr 11, 2025 Risk: low
  On April 11, 2025, Ceribell, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific
• Ceribell, Inc. Reports Director Changes and Officer Compensation Updates — 8-K · Mar 14, 2025 Risk: low
  Ceribell, Inc. announced on March 10, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported the departu
• 10-K Filing — 10-K · Feb 25, 2025
• 8-K Filing — 8-K · Jan 13, 2025
• Ceribell, Inc. Files 10-Q, Details Financials and IPO — 10-Q · Nov 12, 2024 Risk: medium
  Ceribell, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition, including its IPO and various financial
• SC 13G Filing — SC 13G · Nov 7, 2024
• Longitude Capital Boosts Ceribell Stake to 20.1% — SC 13D · Oct 22, 2024 Risk: medium
  On October 22, 2024, Longitude Capital Partners IV, L.P. and related entities, including Juliet Tammenoms Bakker and Patrick G. Enright, reported a change in be
• Ceribell, Inc. Files 8-K with Corporate Updates — 8-K · Oct 15, 2024 Risk: low
  Ceribell, Inc. filed an 8-K on October 15, 2024, reporting on several items including amendments to its articles of incorporation or bylaws, other events, and f
• Ceribell, Inc. Files IPO Amendment — S-1/A · Oct 9, 2024 Risk: medium
  Ceribell, Inc. filed an S-1/A amendment on October 9, 2024, for its initial public offering. The company, based in Sunnyvale, California, is registering an unsp
• Ceribell, Inc. Files S-1/A Amendment for IPO — S-1/A · Oct 7, 2024 Risk: medium
  Ceribell, Inc. filed an S-1/A amendment on October 7, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to register an un
• Ceribell, Inc. Files S-1/A for IPO — S-1/A · Sep 19, 2024 Risk: medium
  Ceribell, Inc. filed an S-1/A amendment on September 19, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Sunnyvale, Ca
• Ceribell, Inc. Files S-1 for Public Offering — S-1 · Aug 26, 2024 Risk: medium
  Ceribell, Inc. filed an S-1 registration statement on August 26, 2024, to offer its securities. The company, incorporated in Delaware with its principal executi

Risk Profile

Risk Assessment: Of CBLL's 20 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Ceribell, INC.'s most recent 10-Q filing (Nov 4, 2025):

• Revenue: $64.279M
• Net Income: -$39.885M
• EPS: Not explicitly stated for the 9-month period, but Net Loss Per Share for Q3 2025 was $0.37
• Debt-to-Equity: Not Disclosed
• Cash Position: $168.5M
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Dr. Shayan Mostajabi
• Mr. David L. Schlotterbeck
• David Foehr
• Scott Blumberg
• Juliet Tammenoms Bakker
• Patrick G. Enright
• Jane Chao, Ph.D.

Industry Context

Ceribell operates in the medical device sector, specifically focusing on diagnostic solutions. The industry is characterized by rapid technological advancements, significant R&D investment, and a complex regulatory landscape. Companies often face challenges related to market adoption, reimbursement policies, and competition from established players and innovative startups.

Top Tags

sec-filing (5) · amendment (4) · ipo (4) · filing (3) · financials (3) · Neurology (2) · Growth Stock (2) · material-definitive-agreement (2) · regulatory-filing (2) · proxy-statement (2)

Key Numbers

• Total Revenue (9 months): $64.279M — Increased 37% from $46.910M in 2024
• Net Loss (9 months): $39.885M — Widened from $27.879M in 2024
• Sales & Marketing Expense (9 months): $54.024M — Increased from $33.812M in 2024
• Research & Development Expense (9 months): $14.081M — Increased from $9.649M in 2024
• Cash & Cash Equivalents (Sept 30, 2025): $23.739M — Decreased from $194.370M at Dec 31, 2024
• Total Liquidity (Sept 30, 2025): $168.5M — Comprised of cash and marketable securities
• Accumulated Deficit (Sept 30, 2025): $206.8M — Reflects cumulative operating losses
• Net Cash Used in Operating Activities (9 months): $30.034M — Increased from $25.068M in 2024
• Common Shares Outstanding (Sept 30, 2025): 37,048,397 — Increased from 35,850,606 at Dec 31, 2024
• Net Loss Per Share (Q3 2025): $0.37 — Lower than $1.85 in Q3 2024 due to increased share count
• Commission File Number: 001-42364 — SEC filing identifier for Ceribell, Inc.
• IRS Employer Identification No.: 47-1785452 — Tax identification for Ceribell, Inc.
• Q2 2025 Revenue: $12.5M — Increased 22.5% from $10.2M in Q2 2024, driven by product and subscription sales.
• Q2 2025 Net Loss: $15.3M — Widened from $14.8M in Q2 2024, indicating increased operational costs despite revenue growth.
• Accumulated Deficit: $344.0M — As of June 30, 2025, highlighting significant historical losses and the need for future capital.

Frequently Asked Questions